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A TIME magazine cover story, entitled ‘The Angelina Effect’, published 
in May 2013, reported that famous and influential actress Angelina 
Jolie had undergone an elective double mastectomy, in the hope of 
reducing her genetically high risk of breast cancer. The probability 
that she would develop breast cancer was estimated at a staggering 
87%. The magazine regarded the ‘revelation’ as ‘so arresting’ that it 
called it a ‘cultural and medical earthquake’.[1] Jolie’s announcement 
was quickly followed by a landmark decision by the United States’ 
Supreme Court in June 2013.  It dealt with the patenting of the very 
genes for which Jolie had been tested, and which ultimately led her 
to have the preventive procedure. These, by now much publicised, 
genes, which correlate to the significantly increased risk of hereditary 
breast and ovarian cancer, are commonly known as the BRCA1 and 
BRCA2 genes. 
The term ‘gene patent’ is often used but mostly misunderstood. It 
should first be placed in its proper context, albeit a simplistic context 
from both legal and scientific perspectives. The term is something of 
a misnomer: it is important to make it clear that a gene as it exists in 
nature, such as a naturally occurring gene in the human body, cannot 
literally be patented.[2] Patent laws typically exclude discoveries from 
patentability.[3,4] Hence, the subjects of ‘gene patents’ are, generally, 
the modification of a naturally occurring genetic sequence, or the 
development of a process for diagnosis or treatment based on naturally 
occurring genetic information – that is, the processes and products 
created in laboratories through human effort and ingenuity.[5] 
It is also a misconception that the granting of a ‘gene patent’ can be 
equated to ‘ownership’, in that a ‘patented gene’ would in all respects 
be off limits to anyone else to study or use. A patent right is far more 
restricted: it merely provides a negative right to exclude others from 
performing certain actions in relation to the product or process, 
which should in principle be strictly defined in the patent application 
and the patent itself.[2] The South African Patents Act, for example, 
states in Section 45(1): ‘The effect of a patent shall be to grant to the 
patentee … the right to exclude other persons from making, using, 
exercising, disposing or offering to dispose of, or importing the 
invention, so that he or she shall have and enjoy the whole profit and 
advantage accruing by reason of the invention’.[3] 
The landmark US Supreme Court Decision
In the much-awaited decision of Association for Molecular Pathology v. 
Myriad Genetics Inc,[6] the United States Supreme Court endeavoured 
to clarify whether a naturally occurring segment of DNA is eligible 
for patent, in terms of United States patent law, by virtue of the fact 
that the segment had been isolated from the rest of the human 
genome. The respondent was Myriad Genetics, a leading molecular 
diagnostic company which dedicates itself to the discovery and 
commercialisation of transformative tests which assess a person’s 
risk of developing a disease, disease progression, and recurrence,[7] 
and had made a valuable medical breakthrough. Myriad discovered 
the precise location and sequence of the BRCA1 and BRCA2 genes 
on the human genome. Changes (so-called mutations) in the genetic 
sequence of these two genes can substantially increase a person’s risk 
of developing breast and ovarian cancer. Armed with the knowledge 
of where these genes were located, Myriad developed diagnostic 
tests that can be used to detect mutations in the BRCA1 and BRCA2 
genes, and thus assess whether a person faces this increased risk. [6] 
By July 2013, one of Myriad’s world leading genetic tests, called 
BRACAnalysis, had been used by more than 1 million women to assess 
their risk of hereditary breast and ovarian cancer.[7] 
After finding the location and sequence of these two genes, Myriad 
managed to obtain a number of patents which, if valid, would give 
Myriad not only the exclusive right to isolate a person’s BRCA1 and 
BRCA2 genes, but also the exclusive right to synthetically create 
BRCA-complementary DNA (so-called cDNA). Myriad held that it was 
its exclusive right to manipulate BRCA DNA by the use of either of 
these methods, and that it could exclude others from doing so. 
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After Myriad made its breakthrough discovery of the two BRCA 
genes, other entities also provided similar genetic testing services. 
One person who regularly used genetic testing for his patients was 
the petitioner in the Supreme Court case at hand, Dr Harry Ostrer. 
He routinely sent samples of BRCA1 and BRCA2 DNA for testing to 
the Genetic Diagnostic Laboratory of the University of Pennsylvania. 
Myriad became aware of this practice and notified both the 
laboratory and Dr Ostrer that they were infringing Myriad’s patents. 
The laboratory gave in to Myriad’s demands and ceased doing genetic 
testing associated with Myriad’s patents. Myriad also filed patent 
infringement actions against many other entities that provided BRCA 
testing services, in this way entrenching itself as the only entity in the 
United States providing BRCA testing services.[6] 
Some years after Myriad first accused him of infringing its BRCA 
genetic testing patents, Dr Ostrer along with a divergent group 
which included cancer patients, medical doctors, academics and a 
number of advocacy groups, collectively filed a lawsuit to challenge 
the validity of a number of Myriad’s patents associated with its 
discovery of the location of the BRCA1 and BRCA2 genes. The District 
Court granted summary judgment to the petitioners, based on its 
conclusion that Myriad’s patent claims, including the claims relating 
to the synthetically created cDNA, were invalid, as they covered 
products of nature.[8] On appeal, the Federal Circuit Court reversed 
the decision of the District Court and held that both isolated DNA and 
synthetically created cDNA were eligible for patent.[9]
It was clear that the Supreme Court had the unenviable task 
of providing clarity and certainty on some hugely important and 
fundamental human DNA patenting issues, which provoked strong 
and obviously divergent views. The Court’s decision centres on what 
it describes as a ‘long held’ and ‘important implicit exception’, citing its 
2012 decision in Mayo Collaborative Services v. Prometheus Laboratories 
Inc,[10] to Section 101 of the United States’ Patent Act. Section 101 
states that ‘whoever invents or discovers any new and useful … 
composition of matter, or any new and useful improvement thereof, 
may obtain a patent therefore’.[11] The relevant ‘important implicit 
exception’ to Section 101 states that, the ‘laws of nature, natural 
phenomena, and abstract ideas are not patentable’.[6] According to the 
Supreme Court, the ‘laws of nature, natural phenomena, and abstract 
ideas’ are ‘the basic tools of scientific and technological work’, and are 
not eligible for patent protection. Without this exception, the Court 
argues, there is the risk that ‘future innovation premised upon’ these 
basic tools would be inhibited – and such innovation is the reason 
patents exist. Reiterating statements made in the Mayo decision, 
the Court explains that ‘patent protection strikes a delicate balance 
between creating “incentives that lead to creation, invention and 
discovery” and “impeding the flow of information that might permit, 
indeed, spur, innovation”.’[6]
In contextualising Myriad’s discovery, the Court states that it is 
beyond contention that: (i) the genetic information contained in the 
BRCA1 and BRCA2 genes was not created by Myriad, nor altered by 
Myriad in any way; (ii) the location and order of the BRCA1 and BRCA2 
genes were present in nature before Myriad discovered the genes; 
and (iii) Myriad did not create or in any way alter the DNA’s genetic 
structure. What Myriad did do was to pinpoint the exact location of 
the BRCA1 and BRCA2 genes.
Therefore, the question is whether the fact that Myriad located these 
genes would entitle the company to claim patent rights on them. 
Writing for a unanimous court, Justice Clarence Thomas answered: 
‘Myriad did not create anything. To be sure, it found an important and 
useful gene, but separating that gene from its surrounding genetic 
material is not an act of invention. Groundbreaking, innovative, 
or even brilliant discovery does not by itself satisfy the Section 101 
inquiry.’ According to the Court, Myriad’s patent claim ‘fell squarely 
within the law of nature exception. … Myriad found the location of 
the BRCA1 and the BRCA2 genes, but the discovery, by itself, does not 
render the BRCA genes “new… composition[s] of matter,” … that are 
patent eligible.’[6]  
Importantly, though, the Court also distinguished between the 
patentability of a naturally occurring isolated DNA sequence and that 
of synthetically created cDNA. Justice Thomas, affirming in part the 
Federal Circuit judgment, wrote: ‘The lab technician unquestionably 
creates something new when cDNA is made. cDNA retains the 
naturally occurring exons of DNA, but is distinct from the DNA from 
which it is derived. As a result, cDNA is not a “product of nature” and 
is patent eligible under Section 101 … ’.[6]
The judgment concluded by clearly indicating that its decision 
does not implicate: (i) any method patents; (ii) any patents regarding 
new applications of knowledge about the BRCA1 and BRCA2 genes; 
or (iii) the patentability of DNA that was scientifically altered through 
changing the order of naturally occurring nucleotides. Rather, its 
decision ‘merely hold[s] that genes and the information they encode 
are not patent eligible under Section 101 simply because they have 
been isolated from the surrounding genetic material’.[6]
The position in other jurisdictions
Apart from the US, Europe and Japan are the most notable 
jurisdictions in biotechnological innovation. Their position regarding 
the patentability of isolated DNA has been summarised by Professor 
Joseph Straus, a biotechnological patent law scholar, Director Emeritus 
of the renowned Max Planck Institute for Intellectual Property, 
Competition and Tax Law, and current incumbent of the National 
Intellectual Property Management Office (NIPMO) Chair of Intellectual 
Property Law and Innovation. In Association for Molecular Pathology et 
al. v. United States Patent and Trademark Office, et al.,[8] (the court of first 
instance in the Supreme Court’s Myriad decision), Straus was asked to 
submit a declaration[12] informing the District Court about the position 
regarding the patentability of isolated DNA in Europe. He described 
the ‘common ground’ that regarding the patenting of isolated DNA 
has been reached by the European Patents Office, the US Patent and 
Trademark Office, and the Japanese Patent Office: the inventor who 
first identifies a gene and its useful function (thus, a gene ‘available for 
use in diagnosis or therapy’) can expect that patent offices around the 
world will accept that a patent can be granted for such an invention.
With reference to the European Parliament and the Council’s 
directive on the legal protections of biotechnological inventions[13] 
in Europe, Professor Straus explains that, assuming that a DNA 
sequence is novel (i.e. was not previously publicly known or used), 
and the other criteria for patentability (utility, non-obviousness, and 
sufficient disclosure) are met, the isolated substance of the DNA 
itself is patentable. He informed the Court: ‘Specifically, the approach 
adopted by the EU Directive is that a nucleic acid corresponding 
to a complete or part of a gene, even if its structure is identical to 
that of a natural element, may constitute a patentable invention, if 
isolated from the human body or otherwise technically produced…. 
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Indeed, the natural pre-existence of biological material alone does 
not constitute a patentability obstacle.’ Expressing his opinion 
on Myriad’s patents under European patent law, Professor Straus 
concluded: ‘Under the EU Directive, the Implementing Regulations of 
the European Patent Convention (“EPC”) and case law interpretation 
of it, “isolated and purified” DNA molecules are patent-eligible subject 
matter. Thus, Myriad’s isolated DNA claims are patent-eligible.’[12] 
The position in Australia seems to be comparable to the European 
approach. Earlier this year in Cancer Voices Australia v. Myriad Genetics 
Inc.,[14] the Australian Federal Court tracked the more expansive 
European approach and ruled that the process of isolating or 
extracting DNA often requires extensive skill and investment, and 
accordingly the granting of a patent as a reward for the research 
and intellectual effort expended is justified. The Court found it ‘an 
unhelpful approach’ to ask whether a composition of matter is a 
‘product of nature’. It added that DNA as it exists inside cells of the 
human body is not patentable. However, isolated DNA is patentable 
as long as it still meets the patentability criteria of novelty, usefulness, 
and an inventive step.[15] 
Conclusion
The decision of the US Supreme Court will undoubtedly have a 
significant impact on biotechnological innovation. It will be viewed 
by many as a major victory, especially by those concerned more with 
the moral and ethical dilemmas and implications of human gene 
patenting.[16,17] On a more practical level, many will rejoice in the 
perceived greater freedom to research, test, diagnose, and develop 
without impediment. The reality, however, is that this decision will 
also have substantial negative ramifications for past and future human 
genetic discovery and innovation. This decision signals the green 
light for opportunistic and unwarranted attacks on numerous already 
existing gene patents deservedly granted for substantial investment 
in time, intellectual effort, and financial resources. Furthermore, it 
could potentially deter those who must decide whether to expend 
substantial investments on future innovation and discovery, for which 
the critical incentive has essentially now been removed. 
The Supreme Court’s ‘sledgehammer’ approach in finding Myriad’s 
patents ineligible will be broadly applied to gene patents generally, 
as well as to DNA of plant, animal or microbial origin. This will surely 
have profound implications for future developments and innovation 
that will reach much further than the limited context of Myriad’s 
BRCA gene patents.[2] It is suggested that the broader, more measured 
European approach to genetic patenting, which is not focused 
on a strict patent eligibility doctrine but which also includes the 
use of other patentability criteria (such as non-obviousness, utility, 
and sufficient disclosure) is sounder. This would still allow for the 
patenting of truly deserved discoveries and inventions, while keeping 
in check problematic and inappropriate gene patents that are not 
worthy of patent protection.[2,18] 
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